Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry
Taxiarchis Kourelis(Mayo Clinic in Arizona), Angela Dispenzieri(Mayo Clinic), Morie A. Gertz(Medical University of South Carolina), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Steven R. Zeldenrust, Surendra Dasari(Mayo Clinic in Arizona), Roman M. Zenka(Mayo Clinic in Florida), Paul J. Kurtin(Mayo Clinic), Jason D. Theis(Mayo Clinic), Marina Ramı́rez-Alvarado(WinnMed)
Cited by 166
Related Papers
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k